Phage Therapy Center LTD.

What Phage Therapy Center LTD. does

Phage Therapy Center LTD. is a privately held medical clinic founded in 2004 in Tbilisi, Republic of Georgia, that operates the world's first contemporary full-service bacteriophage (phage) therapy clinic. The clinic treats international patients suffering from antibiotic-resistant and chronic bacterial infections — including urinary tract infections, sinusitis, lung infections in cystic fibrosis and bronchiectasis, prostatitis, skin and wound infections, and gastrointestinal infections — using lytic bacteriophages that invade and lyse specific bacterial cells. The treatment portfolio includes commercial phage preparations in liquid, tablet, and spray forms; custom autophage preparations developed in-house when standard preparations are ineffective (typically within a few weeks); and Phage Bioderm / PhagoBioDerm, a biodegradable polymer patch combining phages, antibiotics, and proteolytic enzymes for sustained release in wound and surgical applications.

The business operates as a direct-to-consumer medical tourism clinic. Patients register online, submit bacterial specimens for phage matching, and travel to Tbilisi where the clinic coordinates hotel, transportation, and visa logistics; approximately 20% of registered patients ultimately travel to the clinic, while a subset of others self-treat at home in jurisdictions that permit phage importation. The clinic is staffed by both medical microbiologists and medical doctors, including leadership with deep ties to the G. Eliava Institute of Bacteriophage, Microbiology and Virology and JSC Biochimpharm, the country's primary commercial phage producer. Reported clinical outcomes include pathogen eradication in over 95% of patients without antibiotic use, and the clinic claims treatment of 5,617 registered patients across 120+ countries over its 20+ year operating history.

Revenue is generated through fees for phage therapy services, billed per nosology at $4,000-$6,000 plus ancillary charges for custom autophage development and additional infections treated. The clinic was merged into US-based Phage International Inc. in 2005 and that merger was reversed at the end of 2023, returning ownership to the Georgian entity. The company remains privately held with no disclosed venture capital or institutional funding, no patents or trademarks disclosed, and an unverified regulatory pathway to serve US patients directly given current FDA restrictions on phage importation.

Name

Phage Therapy Center LTD.

Legal name

Phage Therapy Center LTD.

Website

https://phagetherapycenter.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

Phage Therapy Center LTD., founded in 2004 in Tbilisi, Georgia, operates the world's first full-service bacteriophage therapy clinic, treating international patients with antibiotic-resistant and chronic bacterial infections through direct-to-consumer medical tourism and custom phage preparations.

Ownership category

akta.pro rank

Product category

Phage Therapy Medical Services

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071)

akta.pro primary industry

Phage & Phage-Derived Microbiome Modulators (HLAAAFAF)

Keywords

• Bacteriophage therapy services
• Antibiotic resistance treatment
• Custom phage preparations
• Medical tourism clinic
• Chronic infection therapy

Headquarters

HQ city

Tbilisi

HQ country

Georgia

HQ region

Asia

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Treatment Services: The clinic generates revenue through fees for phage therapy medical services, including out-patient care, bacteriophage preparations, assessment, diagnosis, treatment planning, and follow-up care. Additional charges apply for custom autophage development when standard preparations are ineffective, and for additional nosology beyond the primary infection.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Phage Therapy Center is a specialized medical clinic in Tbilisi, Georgia that provides bacteriophage-based treatment and diagnostics for a broad range of acute and chronic bacterial infections, including antibiotic-resistant infections and complex chronic biofilm-based conditions. Its core service includes specimen-based phage matching, personalized treatment programs, custom Autophage preparation when standard phages are ineffective, and adjunctive wound-care products such as Phage Bioderm for surgical and chronic wound applications.

Product overview

Phage Therapy Center is a specialized medical clinic providing bacteriophage therapy services for patients with antibiotic-resistant and chronic bacterial infections. The company offers a comprehensive treatment ecosystem centered on its core bacteriophage therapy service, supplemented by laboratory testing services (bacteriological tests, phage sensitivity testing), custom phage preparations (Autophage), pharmaceutical products (Phage Bioderm), and patient management services (Patient Portal, Treatment Logistics Plan). The portfolio includes both clinical services and therapeutic products, with treatments available in multiple phage preparation forms (liquid, tablets, spray) for various infection types.

Differentiator

Problem solved

Functional benefit

Products and services

• Bacteriophage Therapy Services Therapeutic application of lytic bacteriophages to treat antibiotic-resistant and difficult-to-treat bacterial infections, including comprehensive bacterial testing, phage matching, and personalized treatment programs for patients from around the world.
• Medical Services (Diagnostics and Adjunctive Care) Comprehensive clinical and laboratory services including bacteriological tests, bacterial isolate characterization, phage sensitivity testing, surgical procedures, and patient follow-up care delivered alongside phage therapy.
• Phage Bioderm Biodegradable polymer patch incorporating bacteriophages (and in some configurations antibiotics and proteolytic enzymes) into an amino acid-based material that safely biodegrades to tissue-absorbable elements over a chemically programmed timed release, used for treatment of infected venous stasis ulcers and non-healing wounds.
• Autophage (Custom Phage Preparation) Personalized phage preparation developed at the Tbilisi laboratory, matched to a patient's specific bacterial strain when commercial phage preparations are ineffective. Custom development typically takes a few weeks and is offered at additional cost dependent on laboratory time required.
• Phage Preparations Bacteriophage preparations produced in various forms (liquid, tablets, spray), including polyvalent and monophage preparations used to treat different types of bacterial infections.
• Travel and Treatment Organization Services Assistance with trip organization for international patients, including hotel reservations, visa help, airport transportation, and coordination between hotel and clinic during the treatment stay.

Quantifiable outcome

• Over 95% of patients have successful eradication of the pathogen(s) causing their infection without the use of antibiotics
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• G. Eliava Institute of Bacteriophage, Microbiology and VirologycoreStrategic or Co-development PartnerThe Eliava Institute — operating under the Georgian Academy of Sciences — is the historic center of phage expertise, having worked on phage production since the 1930s. It supplied the original scientific founders for Phage Therapy Center and remains the source of phage preparations and expertise.
• JSC BiochimpharmcoreStrategic or Co-development PartnerFormed in 1994 when the production group separated from the Eliava Institute. Mass produces two highly effective polyvalent bacteriophage preparations and several monophage preparations. Biochimpharm's manufacturing capabilities are described as the world's best in terms of quality, consistency and capacity. Serves as a key phage preparation supplier.
• Research Center for Medical Polymers and Biomaterials (RCMPB)coreStrategic or Co-development PartnerOne of the two original founding institutions of Phage Therapy Center. RCMPB contributed the novel technology for incorporating bacteriophages into biodegradable polymer materials, leading to the development of Phage Bioderm.
• Ludwik Hirszfeld Institute of Immunology and Experimental Therapy (Polish Academy of Science)minorStrategic or Co-development PartnerLocated in Wroclaw, Poland, this institute conducts phage therapy research and clinical practice, combining research and education with clinical application. Part of the broader phage therapy research community.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Eligo Bioscience: French biotech developing phage-derived products (Eligobiotics) for precision microbiome modulation and resistant infections. Comparable in phage-based therapeutic modality but focuses on engineered payloads rather than classical phage therapy.
• Locus Biosciences: US clinical-stage company developing engineered phage (crPhage) products targeting antibiotic-resistant bacteria including E. coli and S. aureus. Comparable therapeutic modality (phage-based anti-infectives) but uses engineered rather than naturally occurring phage cocktails.
• ContraFect Corporation: US clinical-stage biopharmaceutical company developing direct lytic agents (including phage-derived lysins) for serious antibiotic-resistant infections. Comparable in addressing drug-resistant bacterial infections but uses lysin proteins derived from phages rather than whole phage therapy.

Regional players

• Technophage: Portugal-based clinical phage therapy company developing personalized and off-the-shelf phage products for bacterial infections. Comparable in offering personalized phage therapy but operates in Europe rather than serving as an international medical tourism destination like Phage Therapy Center.

Direct peers

• Phagelux: China-based clinical-stage phage company developing phage cocktails for antibiotic-resistant infections in human health and agriculture. Comparable therapeutic modality and target indications, but operates primarily in Asia rather than as a global medical tourism destination.
• Adaptive Phage Therapeutics: US-based clinical-stage phage therapy company developing personalized phage treatments for antibiotic-resistant infections. Highly comparable to Phage Therapy Center in target indication (drug-resistant bacterial infections) and customization model, but operates under the US FDA regulatory framework rather than the Georgian approved-therapy regime.
• Armata Pharmaceuticals: Clinical-stage phage therapeutics company (formed via merger of AmpliPhi Biosciences and C3J Therapeutics) developing phage candidates for resistant infections including Staphylococcus aureus and Pseudomonas aeruginosa. Comparable to Phage Therapy Center in therapeutic modality and indication focus.
• Intralytix: US-based phage products company with FDA-approved phage products for food safety and a clinical pipeline for human therapeutic use. Comparable in phage technology platform but with a more diversified portfolio including non-therapeutic applications.

Others

• Eliava Institute of Bacteriophage, Microbiology and Virology: Georgian Academy of Sciences institute and the historical global center of phage expertise since the 1930s. Founding partner and supplier of phage preparations to Phage Therapy Center; also operates its own clinical phage therapy practice. Closely adjacent rather than competing — partnership-driven rather than competitor.
• JSC Biochimpharm: Georgian manufacturer spun off from the Eliava Institute in 1994, mass-producing polyvalent and monophage preparations described as having the world's best quality and capacity. Functions as a key supply-side partner to Phage Therapy Center rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phage Therapy Center LTD.